Corcept Therapeutics Inc
NASDAQ:CORT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.1
60.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Corcept Therapeutics Inc
Wall Street
Price Targets
CORT Price Targets Summary
Corcept Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
CORT
is 76.4 USD
with a low forecast of 67.67 USD and a high forecast of 84 USD.
CORT Last Price Targets
Corcept Therapeutics Inc
The latest public price target was made on Oct 18, 2024 by
Swayampakula Ramakanth
from
H.C. Wainwright
,
who expects
CORT
stock to
rise by 58%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Swayampakula Ramakanth
H.C. Wainwright
|
80
USD
Upside 58% |
2 months ago
Oct 18, 2024
|
Corcept Therapeutics (CORT) PT Raised to $80 at H.C. Wainwright
StreetInsider
|
Joon Lee
Truist Financial
|
76
USD
Upside 50% |
2 months ago
Sep 30, 2024
|
Corcept Therapeutics price target raised to $76 from $65 at Truist
TheFly
|
Edward Nash
Canaccord Genuity
|
78
USD
Upside 54% |
4 months ago
Aug 15, 2024
|
Canaccord Genuity Reiterates Buy Rating on Corcept Therapeutics (CORT)
StreetInsider
|
David Amsellem
Piper Sandler
|
38
USD
Downside 25% |
4 months ago
Jul 30, 2024
|
Corcept Therapeutics (CORT) PT Raised to $38 at Piper Sandler
StreetInsider
|
|
Swayampakula Ramakanth
H.C. Wainwright
|
45
USD
Downside 11% |
4 months ago
Jul 30, 2024
|
Corcept Therapeutics (CORT) PT Raised to $45 at H.C. Wainwright
StreetInsider
|
|
Edward Nash
Canaccord Genuity
|
38
USD
Downside 25% |
6 months ago
Jun 12, 2024
|
Canaccord Genuity Reiterates Buy Rating on Corcept Therapeutics (CORT)
StreetInsider
|
|
David Amsellem
Piper Sandler
|
35
USD
Downside 31% |
6 months ago
Jun 10, 2024
|
Piper Sandler Reiterates Overweight Rating on Corcept Therapeutics (CORT)
StreetInsider
|
|
Joon Lee
Truist Financial
|
65
USD
Upside 28% |
6 months ago
Jun 4, 2024
|
Corcept Therapeutics (CORT) PT Raised to $65 at Truist Securities
StreetInsider
|
|
Swayampakula Ramakanth
H.C. Wainwright
|
40
USD
Downside 21% |
7 months ago
May 2, 2024
|
Corcept Therapeutics (CORT) PT Raised to $40 at H.C. Wainwright
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is CORT's stock price target?
Price Target
76.4
USD
According to Wall Street analysts, the average 1-year price target for
CORT
is 76.4 USD
with a low forecast of 67.67 USD and a high forecast of 84 USD.
What is Corcept Therapeutics Inc's Revenue forecast?
Projected CAGR
29%
For the last 8 years the
compound annual growth rate for
Corcept Therapeutics Inc's revenue is
33%.
The projected
CAGR
for the next 4 years is
29%.
What is Corcept Therapeutics Inc's Operating Income forecast?
Projected CAGR
62%
The
compound annual growth rate
of Corcept Therapeutics Inc's operating income for the next 4 years is
62%.
What is Corcept Therapeutics Inc's Net Income forecast?
Projected CAGR
49%
The
compound annual growth rate
of Corcept Therapeutics Inc's net income for the next 4 years is
49%.
You don't have any saved screeners yet
